GlycoEra has developed a game-changing protein engineering and production platform to build a high-value pipeline of medicines. Our versatile platform enables targeted degradation of circulating and membrane proteins to alleviate diseases. Our innovative, first-in-class product candidates will treat diseases with high unmet medical need in autoimmune, oncology, neurology and infectious disease indications. GlycoEra is advancing a range of assets towards human clinical studies.
GlycoEra’s CustomGlycan enables the rational engineering of glycan structures at specific sites within recombinant proteins. GlycoEra’s approach leverages naturally occurring scavenging receptors that bind and eliminate specific glycan-containing proteins for degradation. The platform’s ability to degrade circulating and membrane proteins allows GlycoEra to pursue multiple novel targets for disease intervention, including hard to drug proteins, multimeric aggregates or membrane proteins that are conformationally versatile.